- Home
- WAT
as 12-18-2024 12:44pm EST
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | MILFORD |
| Market Cap: | 22.5B | IPO Year: | 1995 |
| Target Price: | $374.75 | AVG Volume (30 days): | 507.2K |
| Analyst Decision: | Hold | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 10.48 | EPS Growth: | -4.76 |
| 52 Week Low/High: | $279.24 - $397.02 | Next Earning Date: | 02-04-2025 |
| Revenue: | $2,905,147,000 | Revenue Growth: | -3.01% |
| Revenue Growth (this year): | 0.53% | Revenue Growth (next year): | 5.59% |
Latest Waters Corporation News
WAT Breaking Stock News: Dive into WAT Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Waters Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Argus Research
8 days ago
WAT: Raising target price to $410.00
CNW Group
8 days ago
Waters Highlights Continued Progress Towards Sustainability Commitments
Simply Wall St.
10 days ago
Waters (NYSE:WAT) Achieves Strong Q3 Performance with Innovative Product Adoption and Revenue Growth
Argus Research
15 days ago
WAT: Lowering target price to $406.00
Morningstar Research
22 days ago
Analyst Report: Waters Corporation
Investing.com
a month ago
Elf Beauty says short-seller report is 'without merit', analysts defend
PR Newswire
a month ago
Waters Corporation to Present at the Evercore 2024 HealthCONx Conference
Compare WAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "WAT Waters Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.